Welcome to our dedicated page for Novartis news (Ticker: NVS), a resource for investors and traders seeking the latest updates and insights on Novartis stock.
Novartis AG reports pharmaceutical developments across prescription medicines, late-stage clinical programs and product collaborations. News for NVS commonly covers FDA approvals and label updates for therapies such as Rhapsido® for chronic spontaneous urticaria, Leqvio® for LDL-C reduction, Vanrafia® for IgA nephropathy and Fabhalta® in rare kidney disease, alongside clinical data for immunology and autoimmune programs including ianalumab and Cosentyx®.
The company’s updates also address cardiovascular, renal, metabolic, oncology, neuroscience and immunology priorities, including pipeline readouts, regulatory decisions, medical-congress presentations and licensing activity for new therapeutic assets.
Summary not available.
Summary not available.
Novartis presented new data for Piqray (alpelisib) at the San Antonio Breast Cancer Symposium, demonstrating significant benefits in patients with HR+/HER2- metastatic breast cancer (mBC) and PIK3CA mutations. The BYLieve study showed a median overall survival of 26.4 months for patients treated with Piqray and fulvestrant after CDK4/6 inhibition. Approximately 48.7% of patients showed no disease progression at six months in the cohort treated after chemotherapy or endocrine therapy. No new safety signals were observed, confirming the drug's tolerability.
AavantiBio has appointed Dr. Jenny Marlowe as Chief Scientific Officer. She brings nearly 15 years of experience in the biopharmaceutical sector, previously serving at Bluebird Bio (NASDAQ: BLUE) as VP of Preclinical & Translational Development. Dr. Marlowe will lead scientific research and preclinical development at AavantiBio, which focuses on gene therapies for rare diseases. The company has secured over $107 million in Series A financing and is advancing its gene therapy pipeline, including partnerships with leading organizations such as the University of Florida.
On September 19, 2021, Novartis announced the final overall survival analysis of the Phase III MONALEESA-2 study for Kisqali (ribociclib) combined with letrozole in postmenopausal women with HR+/HER2- advanced breast cancer. The treatment showed a statistically significant median overall survival improvement (63.9 vs. 51.4 months) and a 12-month delay in chemotherapy initiation compared to letrozole alone. No new safety signals were reported. Novartis plans to submit these findings to health authorities for label updates, reinforcing Kisqali's position in advanced breast cancer treatment.
Ionis Pharmaceuticals announced significant progress for pelacarsen, a potential treatment for lipoprotein(a)-driven cardiovascular disease, as the Lp(a) HORIZON study reached 50% enrollment with 4,000 participants. This Phase 3 study aims to support the drug's indication for reducing cardiovascular risk. Ionis received a $25 million milestone payment from Novartis and is eligible for up to $675 million in additional milestones, along with mid-teens to low 20% royalties on pelacarsen sales. This investigational medicine utilizes LICA technology to target elevated Lp(a) levels, a significant risk factor for cardiovascular diseases.
On September 16, 2020, the Novartis US Foundation announced a USD 25 million commitment to tackle health inequities in underserved communities in the United States, particularly focusing on diversity in clinical trials. This funding is aimed at fostering partnerships and enhancing healthcare access amidst the ongoing challenges of the COVID-19 pandemic and racial disparities. Previously, the foundation had committed over USD 10 million to support healthcare systems in overcoming barriers to care. The foundation also seeks to address the underrepresentation of minorities in clinical trials.